Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Neuroblastoma × naxitamab × Clear all

Phase

Phase 2 8 Phase 1 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 1

Interventions

gallium Ga 68 dotatate 2 naxitamab 1 fludarabine 1 eliglustat 1 Vaccines, DNA 1 Thiotepa 1 Temozolomide 1 Rituximab 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Irinotecan 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Ga(III)-DOTATOC 1 6-fluorodopamine 1 3-fluorobenzylguanidine 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03189706 2025-07-02

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡